

Table 1. Demographic characteristics of the study population	
Age (years)	65.2 ± 1.5
Gender (male/female)	102/108
Education (years)	12.5 ± 1.2
Marital status (married/divorced/widowed)	150/10/10
Occupation (retired/employed)	150/10
Income (€ per month)	1,200 ± 200
Comorbidities (hypertension/diabetes/cholesterol)	120/80/60
Medication (antihypertensive/antidiabetic)	100/50
Smoking status (smoker/non-smoker)	30/180
Alcohol consumption (yes/no)	20/190
Family history of heart disease (yes/no)	40/170
Previous heart attack (yes/no)	10/190
Angina pectoris (yes/no)	20/180
Heart failure (yes/no)	10/180
Coronary artery disease (yes/no)	30/170
Peripheral artery disease (yes/no)	10/180
Stroke (yes/no)	10/180
Chronic kidney disease (yes/no)	10/180
Chronic liver disease (yes/no)	10/180
Chronic lung disease (yes/no)	10/180
Chronic pain (yes/no)	10/180
Chronic mental health issues (yes/no)	10/180
Chronic autoimmune disease (yes/no)	10/180
Chronic infectious disease (yes/no)	10/180
Chronic endocrine disease (yes/no)	10/180
Chronic hematological disease (yes/no)	10/180
Chronic neurological disease (yes/no)	10/180
Chronic dermatological disease (yes/no)	10/180
Chronic musculoskeletal disease (yes/no)	10/180
Chronic sensory organ disease (yes/no)	10/180
Chronic reproductive system disease (yes/no)	10/180
Chronic urinary system disease (yes/no)	10/180
Chronic digestive system disease (yes/no)	10/180
Chronic respiratory system disease (yes/no)	10/180
Chronic circulatory system disease (yes/no)	10/180
Chronic integumentary system disease (yes/no)	10/180
Chronic immune system disease (yes/no)	10/180
Chronic nervous system disease (yes/no)	10/180
Chronic sensory system disease (yes/no)	10/180
Chronic motor system disease (yes/no)	10/180
Chronic endocrine system disease (yes/no)	10/180
Chronic reproductive system disease (yes/no)	10/180
Chronic urinary system disease (yes/no)	10/180
Chronic digestive system disease (yes/no)	10/180
Chronic respiratory system disease (yes/no)	10/180
Chronic circulatory system disease (yes/no)	10/180
Chronic integumentary system disease (yes/no)	10/180
Chronic immune system disease (yes/no)	10/180
Chronic nervous system disease (yes/no)	10/180
Chronic sensory system disease (yes/no)	10/180
Chronic motor system disease (yes/no)	10/180
Chronic endocrine system disease (yes/no)	10/180
Chronic reproductive system disease (yes/no)	10/180
Chronic urinary system disease (yes/no)	10/180
Chronic digestive system disease (yes/no)	10/180
Chronic respiratory system disease (yes/no)	10/180
Chronic circulatory system disease (yes/no)	10/180
Chronic integumentary system disease (yes/no)	10/180
Chronic immune system disease (yes/no)	10/180
Chronic nervous system disease (yes/no)	10/180
Chronic sensory system disease (yes/no)	10/180
Chronic motor system disease (yes/no)	10/180
Chronic endocrine system disease (yes/no)	10/180
Chronic reproductive system disease (yes/no)	10/180
Chronic urinary system disease (yes/no)	10/180
Chronic digestive system disease (yes/no)	10/180
Chronic respiratory system disease (yes/no)	10/180
Chronic circulatory system disease (yes/no)	10/180
Chronic integumentary system disease (yes/no)	10/180
Chronic immune system disease (yes/no)	10/180
Chronic nervous system disease (yes/no)	10/180
Chronic sensory system disease (yes/no)	10/180
Chronic motor system disease (yes/no)	10/180
Chronic endocrine system disease (yes/no)	10/180
Chronic reproductive system disease (yes/no)	10/180
Chronic urinary system disease (yes/no)	10/180
Chronic digestive system disease (yes/no)	10/180
Chronic respiratory system disease (yes/no)	10/180
Chronic circulatory system disease (yes/no)	10/180
Chronic integumentary system disease (yes/no)	10/180
Chronic immune system disease (yes/no)	10/180
Chronic nervous system disease (yes/no)	10/180
Chronic sensory system disease (yes/no)	10/180
Chronic motor system disease (yes/no)	10/180
Chronic endocrine system disease (yes/no)	10/180
Chronic reproductive system disease (yes/no)	10/180
Chronic urinary system disease (yes/no)	10/180
Chronic digestive system disease (yes/no)	10/180
Chronic respiratory system disease (yes/no)	10/180
Chronic circulatory system disease (yes/no)	10/180
Chronic integumentary system disease (yes/no)	10/180
Chronic immune system disease (yes/no)	10/180
Chronic nervous system disease (yes/no)	10/180
Chronic sensory system disease (yes/no)	10/180
Chronic motor system disease (yes/no)	10/180
Chronic endocrine system disease (yes/no)	10/180
Chronic reproductive system disease (yes/no)	10/180
Chronic urinary system disease (yes/no)	10/180
Chronic digestive system disease (yes/no)	10/180
Chronic respiratory system disease (yes/no)	10/180
Chronic circulatory system disease (yes/no)	10/180
Chronic integumentary system disease (yes/no)	10/180
Chronic immune system disease (yes/no)	10/180
Chronic nervous system disease (yes/no)	10/180
Chronic sensory system disease (yes/no)	10/180
Chronic motor system disease (yes/no)	10/180
Chronic endocrine system disease (yes/no)	10/180
Chronic reproductive system disease (yes/no)	10/180
Chronic urinary system disease (yes/no)	10/180
Chronic digestive system disease (yes/no)	10/180
Chronic respiratory system disease (yes/no)	10/180
Chronic circulatory system disease (yes/no)	10/180
Chronic integumentary system disease (yes/no)	10/180
Chronic immune system disease (yes/no)	10/180
Chronic nervous system disease (yes/no)	10/180
Chronic sensory system disease (yes/no)	10/180
Chronic motor system disease (yes/no)	10/180
Chronic endocrine system disease (yes/no)	10/180
Chronic reproductive system disease (yes/no)	10/180
Chronic urinary system disease (yes/no)	10/180
Chronic digestive system disease (yes/no)	10/180
Chronic respiratory system disease (yes/no)	10/180

My residence, post office address and citizenship are as stated below, next to my name.

DOMAIN ENCAPSULATION

X is attached hereto.
_____ was filed on _____ as
United States Application Number _____
or PCT International Application Number _____
and was amended on _____
(if applicable)

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d), of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

-1-

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

Application Number

Filing Date

Application Number

Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number

Filing Date

Status -- patented,
pending, abandoned

Application Number

Filing Date

Status -- patented,
pending, abandoned

I hereby appoint the persons listed on Appendix A hereto (which is incorporated by reference and a part of this document) as my respective patent attorneys and patent agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

Send correspondence to John Travis, Reg. No. 43,203, BLAKELY SOKOLOFF TAYLOR & ZAFMAN LLP, 12400 Wilshire Boulevard 7th Floor, Los Angeles, California 90025 and direct telephone calls to John Travis, Reg. No. 43,203, (512) 330-0844.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

APPENDIX A

William E. Alford, Reg. No. 37,764; Farzad E. Amini, Reg. No. 42,261; William Thomas Babbitt, Reg. No. 39,591; Carol F. Barry, Reg. No. 41,600; Jordan Michael Becker, Reg. No. 39,602; Lisa N. Benado, Reg. No. 39,995; Bradley J. Bereznak, Reg. No. 33,474; Michael A. Bernadicou, Reg. No. 35,934; Roger W. Blakely, Jr., Reg. No. 25,831; R. Alan Burnett, Reg. No. 46,149; Gregory D. Caldwell, Reg. No. 39,926; Thomas M. Coester, Reg. No. 39,637; Donna Jo Coningsby, Reg. No. 41,684; Florin Corie, Reg. No. 46,244; Dennis M. deGuzman, Reg. No. 41,702; Stephen M. De Klerk, Reg. No. 46,503; Michael Anthony DeSanctis, Reg. No. 39,957; Daniel M. De Vos, Reg. No. 37,813; Justin M. Dillon, Reg. No. 42,486; Sanjeet Dutta, Reg. No. 46,145; Matthew C. Fagan, Reg. No. 37,542; Tarek N. Fahmi, Reg. No. 41,402; George Fountain, Reg. No. 37,374; James Y. Go, Reg. No. 40,621; James A. Henry, Reg. No. 41,064; Libby N. Hope, Reg. No. 46,774; Willmore F. Holbrow III, Reg. No. 41,845; Sheryl Sue Holloway, Reg. No. 37,850; George W. Hoover II, Reg. No. 32,992; Eric S. Hyman, Reg. No. 30,139; William W. Kidd, Reg. No. 31,772; Sang Hui Kim, Reg. No. 40,450; Walter T. Kim, Reg. No. 42,731; Eric T. King, Reg. No. 44,188; George Brian Leavell, Reg. No. 45,436; Kurt P. Leyendecker, Reg. No. 42,799; Gordon R. Lindeen III, Reg. No. 33,192; Jan Carol Little, Reg. No. 41,181; Robert G. Litts, Reg. No. 46,876; Joseph Lutz, Reg. No. 43,765; Michael J. Mallie, Reg. No. 36,591; Andre L. Marais, under 37 C.F.R. § 10.9(b); Paul A. Mendonsa, Reg. No. 42,879; Clive D. Menezes, Reg. No. 45,493; Richard A. Nakashima, Reg. No. 42,023; Chun M. Ng, Reg. No. 36,878; Thien T. Nguyen, Reg. No. 43,835; Thinh V. Nguyen, Reg. No. 42,034; Dennis A. Nicholls, Reg. No. 42,036; Robert B. O'Rourke, Reg. No. 46,972; Daniel E. Ovanezian, Reg. No. 41,236; Kenneth B. Paley, Reg. No. 38,989; Gregg A. Peacock, Reg. No. 45,001; Marina Portnova, Reg. No. 45,750; William F. Ryann, Reg. No. 44,313; James H. Salter, Reg. No. 35,668; William W. Schaal, Reg. No. 39,018; James C. Scheller, Reg. No. 31,195; Jeffrey S. Schubert, Reg. No. 43,098; George P. Simion, Reg. No. 47,089; Jeffrey Sam Smith, Reg. No. 39,377; Maria McCormack Sobrino, Reg. No. 31,639; Stanley W. Sokoloff, Reg. No. 25,128; Judith A. Szepesi, Reg. No. 39,393; Vincent P. Tassinari, Reg. No. 42,179; Edwin H. Taylor, Reg. No. 25,129; John F. Travis, Reg. No. 43,203; Joseph A. Twarowski, Reg. No. 42,191; Tom Van Zandt, Reg. No. 43,219; Lester J. Vincent, Reg. No. 31,460; Glenn E. Von Tersch, Reg. No. 41,364; John Patrick Ward, Reg. No. 40,216; Mark L. Watson, Reg. No. 46,322; Thomas C. Webster, Reg. No. 46,154; and Norman Zafman, Reg. No. 26,250; my patent attorneys, and Firasat Ali, Reg. No. 45,715; Peggy Susan Howard Avalos, Reg. No. 42,274; Thomas S. Ferrill, Reg. No. 42,532; Charles P. Landrum, Reg. No. 46,855; and Raul Martinez, Reg. No. 46,904, my patent agents, of BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP, with offices located at 12400 Wilshire Boulevard, 7th Floor, Los Angeles, California 90025, telephone (310) 207-3800, and Alan K. Aldous, Reg. No. 31,905; Edward R. Brake, Reg. No. 37,784; Ben Burge, Reg. No. 42,372; Jeffrey S. Draeger, Reg. No. 41,000; Cynthia Thomas Faatz, Reg. No. 39,973; John N. Greaves, Reg. No. 40,362; Seth Z. Kalson, Reg. No. 40,670; David J. Kaplan, Reg. No. 41,105; Peter Lam, Reg. No. 44,855; Charles A. Mirho, Reg. No. 41,199; Leo V. Novakoski, Reg. No. 37,198; Thomas C. Reynolds, Reg. No. 32,488; Kenneth M. Seddon, Reg. No. 43,105; Mark Seeley, Reg. No. 32,299; Steven P. Skabrat, Reg. No. 36,279; Howard A. Skaist, Reg. No. 36,008; Gene I. Su, Reg. No. 45,140; Calvin E. Wells, Reg. No. 43,256; Raymond J. Werner, Reg. No. 34,752; Robert G. Winkle, Reg. No. 37,474; Steven D. Yates, Reg. No. 42,242; and Charles K. Young, Reg. No. 39,435; my patent attorneys, of INTEL CORPORATION; and James R. Thein, Reg. No. 31,710, my patent attorney with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

APPENDIX B

Title 37, Code of Federal Regulations, Section 1.56 Duty to Disclose Information Material to Patentability

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) Prior art cited in search reports of a foreign patent office in a counterpart application, and
 - (2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) Each inventor named in the application;
 - (2) Each attorney or agent who prepares or prosecutes the application; and
 - (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.